middle.news
Zelira Raises US$33M to Advance HOPE® 1 Autism Drug Through FDA Trials
10:22am on Friday 16th of January, 2026 AEDT
•
Healthcare
Read Story
Zelira Raises US$33M to Advance HOPE® 1 Autism Drug Through FDA Trials
10:22am on Friday 16th of January, 2026 AEDT
Key Points
US$32.98 million raised into HOPE® 1 SPV with ThirdGate Capital acquiring 50% stake
SPV valued at approximately US$66 million post-money
Funding to support FDA IND submission and Phase 1 clinical trial initiation
Focus on rare disease Phelan-McDermid Syndrome with autism comorbidity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE